Viking Therapeutics (VKTX) to Release Quarterly Earnings on Wednesday

Viking Therapeutics (NASDAQ:VKTX - Get Free Report) is anticipated to announce its earnings results after the market closes on Wednesday, February 5th. Analysts expect the company to announce earnings of ($0.28) per share for the quarter.

Viking Therapeutics Stock Performance

VKTX traded down $0.89 during trading on Wednesday, reaching $33.43. The stock had a trading volume of 1,635,843 shares, compared to its average volume of 3,583,935. The stock has a market cap of $3.73 billion, a PE ratio of -35.95 and a beta of 0.95. Viking Therapeutics has a one year low of $22.51 and a one year high of $99.41. The business has a 50-day moving average of $42.93 and a 200-day moving average of $54.89.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on VKTX shares. B. Riley started coverage on Viking Therapeutics in a research note on Friday, November 22nd. They set a "buy" rating and a $109.00 price objective on the stock. William Blair reaffirmed an "outperform" rating on shares of Viking Therapeutics in a research note on Wednesday, November 20th. Piper Sandler started coverage on Viking Therapeutics in a research note on Monday, December 2nd. They set an "overweight" rating and a $74.00 price objective on the stock. HC Wainwright reaffirmed a "buy" rating and set a $102.00 price objective on shares of Viking Therapeutics in a research note on Friday, January 17th. Finally, StockNews.com raised Viking Therapeutics to a "sell" rating in a research note on Tuesday, October 15th. One analyst has rated the stock with a sell rating, eleven have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Viking Therapeutics presently has an average rating of "Buy" and an average price target of $106.75.

Insider Buying and Selling

In other Viking Therapeutics news, Director Lawson Macartney sold 2,000 shares of the company's stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $68.67, for a total value of $137,340.00. Following the transaction, the director now directly owns 47,965 shares in the company, valued at $3,293,756.55. This represents a 4.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Brian Lian sold 194,490 shares of the company's stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $42.75, for a total transaction of $8,314,447.50. Following the completion of the transaction, the chief executive officer now owns 2,366,570 shares in the company, valued at $101,170,867.50. This represents a 7.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 301,014 shares of company stock worth $12,920,189 in the last three months. Insiders own 4.70% of the company's stock.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.